ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.1
  1. ホーム
  2. /化合物

デュロキセチン塩酸塩

Duloxetine Hydrochloride

HCID 60834
反応を作成
印刷

データを補完しています。しばらくしてからページを更新すると最新の内容を表示できます

基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
136434-34-9
標準SMILES
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1.Cl
InChIKey
BFFSMCNJSOPUAY-LMOVPXPDSA-N
分子式
C18H20ClNOS
平均分子量
333.9 g/mol
単同位体質量
333.09541294

概要

(S)-duloxetine hydrochloride is a duloxetine hydrochloride in which the duloxetine moiety has S configuration. It has a role as an antidepressant. It contains a (S)-duloxetine.

名称と識別子

優先名称
Duloxetine Hydrochloride
IUPAC
(3S)-N-methyl-3-naphthalen-1-yloxy-3-thiophen-2-ylpropan-1-amine;hydrochloride
現地名
デュロキセチン塩酸塩
英語名
Duloxetine hydrochloride
分子式
C18H20ClNOS
分子量
333.88

名称と別名

DULOXETINE HYDROCHLORIDE136434-34-9Duloxetine HClAriclaimDuloxetine mylanDTXSID9046443LY248686 HClLY-248686 HClDuloxetine (as hydrochloride)NSC-7591129044SC542WDuloxetine Boehringer Ingelheim
名称をさらに表示
デュロキセチン塩酸塩(S)-(+)-N-メチル-3-(1-ナフチルオキシ)-3-(2-チエニル)プロピルアミン塩酸塩ズロキセチン塩酸塩塩酸デュロキセチン塩酸デュロキセチン (JAN)DuloxetimeDuL(S)-DULOXETINE HYDROCHLORIDECS-488LY-248686CAS:136434-34-9S-Duloxetine HCloxetine HydrochL
DTXCID7026443CHEBI:31526DRIZALMA SPRINKLECHEBI:36808DuloxicaineDuciltiaDuloxetine DRHCl, Duloxetine

データベース識別子

CAS
136434-34-9
PubChem CID

物性

構造計算による物性補完中

極性表面積
49.5 Ų
水素結合供与体数
2
水素結合受容体数
3
回転可能結合数
6
重原子数
22
形式電荷
0
複雑度
312

実験および物理化学的性質

Human Drugs · 4 件

Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Serotonin-Norepinephrine Reuptake Inhibitors

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Collision Cross Section168.9 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

物理化学的性質

融点
118 · 118-122°C
闪点
9 ℃ · 9℃
貯蔵温度
room temp
溶解性
2 O: · H2O: ソリュブル5mg/mL (透明溶液、加温)
酸解離定数(Pka)
pKa in DMF-water (66:34): 9.6(at 25℃)
外見
粉
色
白からベージュ
Merck
14 · 14,3465
主な用途
医薬品(低分子化合物)
InChI
InChI=1/C18H19NOS.ClH/c1-19-12-11-17(18-10-5-13-21-18)20-16-9-4-7-14-6-2-3-8-15(14)16;/h2-10,13,17,19H,11-12H2,1H3;1H/t17-;/s3
InChIKey
BFFSMCNJSOPUAY-VOPAOICTNA-N
SMILES
C1(=CC=CS1)[C@H](CCNC)OC1=CC=CC2=CC=CC=C12.Cl |&1:5,r|

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H301 (15.2%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P264+P265, P270, P273, P280, P301+P316, P301+P317, P305+P354+P338, P317, P321, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 66 reports by companies from 14 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Hazard Classes and CategoriesAcute Tox. 3 (15.2%)

毒性情報

Treatment · 1 件

There is no specific antidote to Duloxetine, but if serotonin syndrome ensues, specific treatment (such as with cyproheptadine and/or temperature control) may be considered. In case of acute overdose, treatment should consist of those general measures employed in the management of overdose with any drug. An adequate airway, oxygenation, and ventilation should be assured, and cardiac rhythm and vital signs should be monitored. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion or in symptomatic patients. Activated charcoal may be useful in limiting absorption of duloxetine from the gastrointestinal tract. Administration of activated charcoal has been shown to decrease AUC and Cmax by an average of one-third, although some subjects had a limited effect of activated charcoal. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be beneficial. (L1712)

Exposure RoutesOrally administered duloxetine hydrochloride is well absorbed.
Toxicity Summary · 1 件

Duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake. Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors. The antidepressant and pain inhibitory actions of duloxetine are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS. The mechanism of action of duloxetine in SUI has not been determined, but is thought to be associated with the potentiation of serotonin and norepinephrine activity in the spinal cord, which increases urethral closure forces and thereby reduces involuntary urine loss.

化学と産業

薬理情報

Metabolism/Metabolites · 1 件

The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation. Both CYP2D6 and CYP1A2 catalyze the oxidation of the naphthyl ring in vitro. Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate. The major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine. Route of Elimination: Many additional metabolites have been identified in urine, some representing only minor pathways of elimination. Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces. Half Life: 12 hours (range 8-17 hours)

FDA Pharmacological Classification · 6 件

DULOXETINE HCL

Norepinephrine Uptake Inhibitors [MoA]; Serotonin and Norepinephrine Reuptake Inhibitor [EPC]; Serotonin Uptake Inhibitors [MoA]

DULOXETINE HYDROCHLORIDE

Serotonin Uptake Inhibitors [MoA]; Serotonin and Norepinephrine Reuptake Inhibitor [EPC]; Norepinephrine Uptake Inhibitors [MoA]

DULOXETINE D/R

Serotonin Uptake Inhibitors [MoA]; Norepinephrine Uptake Inhibitors [MoA]; Serotonin and Norepinephrine Reuptake Inhibitor [EPC]

MeSH Pharmacological Classification · 4 件

Compounds capable of relieving pain without the loss of CONSCIOUSNESS.

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

Drugs that selectively block or suppress the plasma membrane transport of SEROTONIN and NORADRENALINE into axon terminals and are used as ANTIDEPRESSIVE AGENTS.

Any drugs that are used for their effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons.

関連反応

18 件
反応記録を作成
HRID 222780 の反応式
HRID 222780生成物としてuspto-grants-2012_06
HRID 222785 の反応式
HRID 222785生成物としてuspto-grants-2012_06
HRID 420011 の反応式
HRID 420011生成物としてuspto-grants-2012_01
HRID 656685 の反応式
HRID 656685生成物としてuspto-grants-2011_12
HRID 656690 の反応式
HRID 656690生成物としてuspto-grants-2011_12
HRID 1176066 の反応式
HRID 1176066生成物としてuspto-grants-2010_11
HRID 1694626 の反応式
HRID 1694626生成物としてuspto-grants-2012_04
HRID 1715781 の反応式
HRID 1715781生成物としてuspto-grants-2010_09
前へ1 / 3 ページ

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
60834
DTXSID
DTXSID9046443
ChEMBL
CHEMBL1200328
ChEBI
CHEBI:31526
UNII
9044SC542W
EC Number
603-962-5

化学的性質

化学的特性White Crystalline Solid

Signs and SymptomsSymptoms of overdose include tremors, convulsions, reduced activity, slow pupillary response, intermittent tremors, and rigidity.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Duloxetine hydrochloride

vMost-DILI-concern

8

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataOral, rat LD<sub>50</sub>: 491 mg/kg for males and 279 mg/kg for females (A308).

安全データ

wgk
3
rtecs
XN0258000
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
hs_code
29349990
risk_code
36/37/38-22-39/23/24/25-23/24/25-11
hazard_code
Xi,Xn,T,F
safety_code
26-36/37-45-16-7
Hazard Classifications
Acute Tox. 4 Oral
ストレージクラス
11 - Combustible Solids

用途と製造

Uses · 1 件

For the acute and maintenance treatment of major depressive disorder (MDD), as well as acute management of generalized anxiety disorder. Also used for the management of neuropathic pain associated with diabetic peripheral neuropathy, and fibromyalgia. Has been used in the management of moderate to severe stress urinary incontinence (SUI) in women.

応用分野 · 4 件

用途セロトニン・ノルアドレナリ ン再取り込み阻害薬(SNRI)です。セロトニ ン・ノルアドレナリン再取り込み部位に選択 的に阻害する作用を示します。

用途セロトニン・ノルアドレナリ ン再取り込み阻害薬(SNRI)です。セロトニ ン・ノルアドレナリン再取り込み部位に選択 的に阻害する作用を示します。

使用Duloxetine Hydrochloride acts as an antidepressant and a dual serotonin and norepinephrine reuptake inhibitor (SNRI) (1,2). Exhibits linear pharmacokinetics in mice and is not associated in any drastic changes of blood pressure or heart rate (3).

一般的な説明Pharmaceutical secondary standards for application in quality control provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards

上流・下流製品情報

上流原料

Carbamic acid, N-methyl-N-[(3S)-3-(1-naphthalenyloxy)-3-(2-thienyl)propyl]-, ethyl ester(S)-3-(メチルアミノ)-1-(2-チエニル)-1-プロパノールDuloxetine Related Compound F (10 mg) ((S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-3-yl)propan-1-amine hydrochloride)N-メチル-N-[(3S)-3-(1-ナフチルオキシ)-3-(2-チエニル)プロピル]カルバミド酸フェニル(±)-デュロキセチン(R)-ズロキセチン塩酸塩ジメチル[(3S)-3-(1-ナフチルオキシ)-3-(2-チエニル)プロピル]アミン(S)-N,N-Dimethyl-[3-(2-thienyl)-3-(1-naphthyloxy)propyl]amine--phosphoric acid (1:1)DULOXETINE MALEATEジメチル[(3S)-3-(1-ナフチルオキシ)-3-(2-チエニル)プロピル]アンモニウム=水素=オキサラート(S)-3-(ジメチルアミノ)-1-(2-チエニル)-1-プロパノール1-フルオロナフタレンクロロぎ酸フェニル

下流製品

Duloxetine iMpurity (alpha-hydroxy)

補足説明

定義ChEBI: A duloxetine hydrochloride in which the duloxetine moiety has S configuration.